JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova Limited has filed its Annual Secretarial Compliance Report for FY 2025-26, as mandated under SEBI Regulation 24A. The report, prepared by independent practicing company secretaries Sanjay Grover & Associates, examined compliance across multiple SEBI regulations including LODR, SAST, Insider Trading, and Employee Benefits regulations. The examination found zero deviations, zero violations, and no fines or penalties during the review period. All seven compliance areas checked show 'Yes' status with no observations. No actions were taken by SEBI or stock exchanges against the company. The report confirms the company maintained proper secretarial standards, adopted required policies, operated a compliant website, preserved documents properly, conducted board performance evaluations, and complied with related party transaction norms.
This is a positive compliance filing indicating clean regulatory standing. For shareholders, it confirms the company maintained strong corporate governance and avoided any SEBI violations during FY 2025-26, which supports investor confidence in the company's governance practices.